Review Article | Published:

Inflammation and cancer

Nature volume 420, pages 860867 (19 December 2002) | Download Citation

Subjects

Abstract

Recent data have expanded the concept that inflammation is a critical component of tumour progression. Many cancers arise from sites of infection, chronic irritation and inflammation. It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration. In addition, tumour cells have co-opted some of the signalling molecules of the innate immune system, such as selectins, chemokines and their receptors for invasion, migration and metastasis. These insights are fostering new anti-inflammatory therapeutic approaches to cancer development.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).

  2. 2.

    Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650–1659 (1986).

  3. 3.

    Tumour immunology: immune recognition and tumor protection. Curr. Opin. Immunol. 14, 161–164 (2002).

  4. 4.

    Spinning molecular immunology into successful immunotherapy. Nature Rev. Immunol. 2, 227–238 (2002).

  5. 5.

    & in Inflammation: Basic Principles and Clinical Correlates (eds Gallin, J. I. & Snyderman, R.) 865–881 (Lipincott, Williams and Wilkinson, Philadelphia, 1999).

  6. 6.

    & The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217–242 (2000).

  7. 7.

    , & Chemokines: agents for the immunotherapy of cancer? Nature Rev. Immunol. 2, 175–184 (2002).

  8. 8.

    , , & Mechanisms of TGF-β signaling in regulation of cell growth and differentiation. Immunol. Lett. 82, 85–91 (2002).

  9. 9.

    & Conditional neoplasms and subthreshold neoplastic states: a study of the tar tumors of rabbits. J. Exp. Med. 73, 365–389 (1941).

  10. 10.

    & The experimental disclosure of latent neoplastic changes in tarred skin. J. Exp. Med. 73, 391–415 (1941).

  11. 11.

    , & Infections as a major preventable cause of human cancer. J. Intern. Med. 248, 171–183 (2000).

  12. 12.

    & Tumor-associated macrophages as targets for cancer therapy. J. Natl Cancer Inst. 90, 1583–1584 (1998).

  13. 13.

    et al. Generation of large numbers of immature and mature dendritic cells from rat bone marrow cultures. Eur. J. Immunol. 28, 811–817 (1998).

  14. 14.

    et al. The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol. Rev. 177, 141–149 (2000).

  15. 15.

    , , & Tumors and inflammatory infiltrates: friends or foes? Clin. Exp. Metastasis 19, 247–258 (2002).

  16. 16.

    , , & Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res. 62, 5069–5075 (2002).

  17. 17.

    et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 161, 947–956 (2002).

  18. 18.

    et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFα and IL-1α. Int. J. Cancer 85, 182–188 (2000).

  19. 19.

    , , , & Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother. Pharmacol. 43, S69–S71 (1999).

  20. 20.

    et al. Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J. Exp. Med. 176, 1165–1174 (1992).

  21. 21.

    , , & Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727–740 (2001).

  22. 22.

    et al. Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int. J. Cancer 65, 112–119 (1996).

  23. 23.

    et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97, 339–345 (2001).

  24. 24.

    et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13, 1382–1397 (1999).

  25. 25.

    , , & MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481–490 (2000).

  26. 26.

    et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737–744 (2000).

  27. 27.

    , & Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res. 55, 562–565 (1995).

  28. 28.

    et al. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J. Natl Cancer Inst. 86, 120–126 (1994).

  29. 29.

    & Chronic inflammation and cancer. Oncology 16, 217–226 (2002).

  30. 30.

    & Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry 63, 854–865 (1998).

  31. 31.

    et al. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc. Natl Acad. Sci. USA 99, 10025–10030 (2002).

  32. 32.

    & The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu. Rev. Microbiol. 54, 615–640 (2000).

  33. 33.

    et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190, 1375–1382 (1999).

  34. 34.

    , & The spatial relationship between stem cells and their progeny in the basal layer of human epidermis: a new view based on whole-mount labeling and lineage analysis. Development 126, 2409–2418 (1999).

  35. 35.

    , & Inflammation is responsible for the development of wound-induced tumors in chickens infected with Rous sarcoma virus. Cancer Res. 54, 4334–4341 (1994).

  36. 36.

    et al. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J. Exp. Med. 196, 641–653 (2002).

  37. 37.

    & The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19, 2468–2473 (2000).

  38. 38.

    et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nature Med. 8, 1089–1097 (2002).

  39. 39.

    , , , & Macrophage control of inflammation: negative pathways of regulation of inflammatory cytokines. Novartis Found. Symp. 234, 120–131 (2001).

  40. 40.

    & Purification of melanoma growth stimulatory activity. J. Cell. Physiol. 129, 375–384 (1986).

  41. 41.

    , & Expression and growth-promoting function of the IL-8 receptor β in human melanoma cells. J. Immunol. 156, 1132–1137 (1996).

  42. 42.

    , , , & Effects of MGSA/GRO alpha on melanocyte transformation. Oncogene 6, 1115–1124 (1991).

  43. 43.

    et al. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins. Int. J. Cancer 73, 94–103 (1997).

  44. 44.

    & Chemokines in cancer. Cytokine Growth Factor Rev. 13, 143–154 (2002).

  45. 45.

    & Inflammation and the development of pancreatic cancer. Surg. Oncol. 10, 153–169 (2002).

  46. 46.

    et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J. Clin. Invest. 102, 465–472 (1998).

  47. 47.

    et al. Detection and localization of Mip-3α/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer 81, 650–657 (1999).

  48. 48.

    & The hallmarks of cancer. Cell 100, 57–70 (2000).

  49. 49.

    et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270, 27348–27357 (1995).

  50. 50.

    et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50–56 (2001).

  51. 51.

    The role of chemoattraction in cancer metastases. BioEssays 23, 674–676 (2001).

  52. 52.

    , , & P-selectin deficiency attenuates tumor growth and metastasis. Proc. Natl Acad. Sci. USA 95, 9325–9330 (1998).

  53. 53.

    et al. Sialyl Lewis X-dependent lung colonization of B16 melanoma cells through a selectin-like endothelial receptor distinct from E- or P-selectin. Cancer Res. 62, 4194–4198 (2002).

  54. 54.

    et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl Acad. Sci. USA 98, 3352–3357 (2001).

  55. 55.

    , , , & Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc. Natl Acad. Sci. USA 99, 2193–2198 (2002).

  56. 56.

    , & L-selectin can facilitate metastasis to lymph nodes in a transgenic mouse model of carcinogenesis. Proc. Natl Acad. Sci. USA 98, 3976–3981 (2001).

  57. 57.

    & Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu. Rev. Med. 51, 511–523 (2000).

  58. 58.

    & Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 12, 88–93 (2001).

  59. 59.

    , & The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18, 7908–7916 (1999).

  60. 60.

    , , , & Antimetastatic effect of flurbiprofen and other platelet aggregation inhibitors. Neoplasma 33, 417–421 (1986).

  61. 61.

    , , & Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. 3, 1679–1683 (1997).

  62. 62.

    Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 13, 135–141 (2002).

  63. 63.

    & Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. Clin. Immunol. 103, 231–242 (2002).

  64. 64.

    & New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161–174 (2002).

  65. 65.

    & Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Rev. Cancer 2, 657–672 (2002).

  66. 66.

    , & Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387–2392 (2002).

  67. 67.

    & Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv. Cancer Res. 84, 231–276 (2002).

  68. 68.

    , , & Neutrophils express tumor necrosis factor-alpha during mouse skin wound healing. J. Invest. Dermatol. 105, 120–123 (1995).

  69. 69.

    et al. Differential regulation of pro-inflammatory cytokines during wound healing in normal and glucocorticoid-treated mice. Cytokine 8, 548–556 (1996).

  70. 70.

    , , & Regulation of keratinocyte growth factor gene expression by interleukin 1. J. Biol. Chem. 269, 10753–10757 (1994).

  71. 71.

    , & Retinal pigment epithelium cells promote the maturation of monocytes to macrophages in vitro. Ophthalmic Res. 29, 31–36 (1997).

  72. 72.

    Wound healing: the role of the macrophage and other immune cells. Shock 4, 233–240 (1995).

  73. 73.

    , , & Cytokines modulate fibroblast phenotype and epithelial-stroma interactions in rat intestine. Gastroenterology 112, 826–838 (1997).

  74. 74.

    et al. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol. Biol. Cell 9, 875–884 (1998).

  75. 75.

    , , , & In vivo regulation of macrophage IL-12 production during type 1 and type 2 cytokine-mediated granuloma formation. J. Immunol. 155, 3546–3551 (1995).

  76. 76.

    et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nature Med. 2, 287–292 (1996).

Download references

Acknowledgements

Supported by grants from the National Institutes of Health, the American Cancer Society, the V Foundation for Cancer Research, the Edward Mallinckrodt Jr Foundation for Medical Research, and the American Association for Cancer Research.

Author information

Affiliations

  1. *Cancer Research Institute, University of California, San Francisco, California 94143 USA

    • Lisa M. Coussens
  2. †Department of Pathology, University of California, San Francisco, California 94143 USA

    • Lisa M. Coussens
  3. ‡Department of Anatomy, University of California, San Francisco, California 94143 USA

    • Zena Werb
  4. §UCSF Comprehensive Cancer Center, University of California, San Francisco, California 94143 USA

    • Lisa M. Coussens
    •  & Zena Werb
  5. coussens@cc.ucsf.edu zena@itsa.ucsf.edu

Authors

  1. Search for Lisa M. Coussens in:

  2. Search for Zena Werb in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nature01322

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing